Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 5/20 | 0.67 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29535019 | 1.00 | UCHL1 (0.67) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL20571008 | 0.92 | UCHL1 (0.61) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL30147617 | 0.92 | UCHL1 (0.61) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL31014046 | 0.86 | UCHL1 (0.52) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL3902861 | 0.86 | UCHL1 (0.52) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL23063791 | 0.86 | NOTUM (0.64) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL25138052 | 0.85 | UCHL1 (0.52) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL868725 | 0.84 | NOTUM (0.65) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| Potassium Ion SCHEMBL31605708 | 0.84 | UCHL1 (0.51) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL868581 | 0.84 | NOTUM (0.65) | UCHL1NOTUMKDM1AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2026-05-28 | — | — | US | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4701735-A1 | HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR | Nested Therapeutics, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | C4 THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250289811-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4606799-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2025-08-27 | — | — | EP | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-2385832-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2015-07-15 | — | — | EP | disclosed |
| US-8906909-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8461157-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-8367663-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| WO-2010150837-A1 | INDOLINE DERIVATIVE | 第一三共株式会社 (JP) | 2010-12-29 | — | — | WO | disclosed |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | UCHL1 4382/4885NOTUM 4208/4885KDM1A 555/4885 |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | UCHL1 62/4885NOTUM 2193/4885KDM1A 364/4885 |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | UCHL1 2326/4885NOTUM 3387/4885KDM1A 137/4885 |
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | PTPN6, PTPN1, PTPN11 | UCHL1 1938/4885NOTUM 3917/4885KDM1A 2286/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | UCHL1 4382/4885NOTUM 4208/4885KDM1A 555/4885 |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | UCHL1 4326/4885NOTUM 4244/4885KDM1A 529/4885 |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | UCHL1 4382/4885NOTUM 4208/4885KDM1A 555/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | UCHL1 62/4885NOTUM 2193/4885KDM1A 364/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | UCHL1 18/4885NOTUM 2701/4885KDM1A 17/4885 |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | CRBN, STUB1, CUL1 | UCHL1 62/4885NOTUM 2193/4885KDM1A 364/4885 |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | KRAS, HRAS, KSR2 | UCHL1 2583/4885NOTUM 4221/4885KDM1A 679/4885 |
| US-20250289811-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK1, MAP3K1, MAPK3 | UCHL1 4477/4885NOTUM 2830/4885KDM1A 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.